ABOS Stock Overview
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Acumen Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.94 |
52 Week High | US$11.31 |
52 Week Low | US$1.81 |
Beta | 0.19 |
1 Month Change | -15.76% |
3 Month Change | -32.41% |
1 Year Change | -40.61% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -85.37% |
Recent News & Updates
Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Shareholder Returns
ABOS | US Biotechs | US Market | |
---|---|---|---|
7D | -13.5% | -0.4% | -0.6% |
1Y | -40.6% | 5.5% | 22.2% |
Return vs Industry: ABOS underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: ABOS underperformed the US Market which returned 22.2% over the past year.
Price Volatility
ABOS volatility | |
---|---|
ABOS Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ABOS's share price has been volatile over the past 3 months.
Volatility Over Time: ABOS's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 52 | Dan O'Connell | acumenpharm.com |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.
Acumen Pharmaceuticals, Inc. Fundamentals Summary
ABOS fundamental statistics | |
---|---|
Market cap | US$176.63m |
Earnings (TTM) | -US$55.94m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs ABOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABOS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$42.32m |
Gross Profit | -US$42.32m |
Other Expenses | US$13.62m |
Earnings | -US$55.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.93 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 11.5% |
How did ABOS perform over the long term?
See historical performance and comparison